457 results on '"Keler, Tibor"'
Search Results
2. Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
3. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin
4. Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice
5. Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering
6. High-Dimensional Phenotypic Mapping of Human Dendritic Cells Reveals Interindividual Variation and Tissue Specialization
7. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
8. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies
9. Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma
10. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets
11. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy
12. Expanding immunotherapy options in cholangiocarcinoma: Role of CD27 agonist in combination with PD-L1 and MEK inhibition on antitumor effect and CD8 + T cells.
13. A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas
14. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy
15. Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s
16. Dual targeting of mast cells and TSLP with a bispecific antibody
17. Abstract 2963: CDX-585, a novel bispecific antibody targeting PD-1 and ILT4
18. Supplementary Table 1 from Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1
19. Supplementary Figure 1 from Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1
20. Data from Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1
21. Supplementary Figure from [89Zr]ZrDFO-CR011 PET Correlates with Response to Glycoprotein Nonmetastatic Melanoma B–targeted Therapy in Triple-negative Breast Cancer
22. Supplementary Data from [89Zr]ZrDFO-CR011 PET Correlates with Response to Glycoprotein Nonmetastatic Melanoma B–targeted Therapy in Triple-negative Breast Cancer
23. Supplementary Table from [89Zr]ZrDFO-CR011 PET Correlates with Response to Glycoprotein Nonmetastatic Melanoma B–targeted Therapy in Triple-negative Breast Cancer
24. Figure A1 from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
25. Supplementary Data from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
26. Table S2 from PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell–Driven Antitumor Immunity
27. Supplementary Table 1 from Phase I Study Utilizing a Novel Antigen-Presenting Cell–Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients
28. Figures S1-S5 from PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell–Driven Antitumor Immunity
29. Supplementary Material from MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB
30. Supplementary Tables and Figures from MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB
31. Data from Phase I Study Utilizing a Novel Antigen-Presenting Cell–Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients
32. Supplementary Figure 2 from Depletion of Dendritic Cells Delays Ovarian Cancer Progression by Boosting Antitumor Immunity
33. Supplementary Figure 1 from Depletion of Dendritic Cells Delays Ovarian Cancer Progression by Boosting Antitumor Immunity
34. Data Supplement from Depletion of Dendritic Cells Delays Ovarian Cancer Progression by Boosting Antitumor Immunity
35. Data from Depletion of Dendritic Cells Delays Ovarian Cancer Progression by Boosting Antitumor Immunity
36. Supplementary Figure 3 from Depletion of Dendritic Cells Delays Ovarian Cancer Progression by Boosting Antitumor Immunity
37. Supplementary Figure Legends from Depletion of Dendritic Cells Delays Ovarian Cancer Progression by Boosting Antitumor Immunity
38. Indoleamine 2,3-Dioxygenase-Expressing Aortic Plasmacytoid Dendritic Cells Protect against Atherosclerosis by Induction of Regulatory T Cells
39. Targeted delivery of a vaccine protein to Langerhans cells in the human skin via the C‐type lectin receptor Langerin
40. Strong association of mast cells with eosinophilic esophagitis‐specific signatures
41. 596 Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab
42. 555 Clinical and pharmacodynamic biomarker results from PORTER, a multi-cohort phase 1 platform trial of combination immunotherapy for metastatic castration-resistant prostate cancer patients
43. 559 Biomarker correlates of clinical response with FLT3L/nivo backbone treatment in the multi-cohort phase 1 PORTER platform trial in metastatic castration-resistant prostate cancer patients
44. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
45. Agonistic anti‐CD27 antibody ameliorates EAE by suppressing IL‐17 production
46. Tissue-specific modifier alleles determine Mertk loss-of-function traits
47. Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
48. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
49. Tissue-specific modifier alleles determine Mertk loss-of-function traits
50. [(89)Zr]ZrDFO-CR011 positron emission tomography correlates with response to glycoprotein non-metastatic melanoma B-targeted therapy in triple negative breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.